Ally Bridge Group NY LLC Makes New Investment in Perspective Therapeutics, Inc. (NYSE:CATX)

Ally Bridge Group NY LLC acquired a new stake in Perspective Therapeutics, Inc. (NYSE:CATX) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 396,242 shares of the company’s stock, valued at approximately $3,951,000. Perspective Therapeutics makes up about 2.4% of Ally Bridge Group NY LLC’s portfolio, making the stock its 21st largest holding. Ally Bridge Group NY LLC owned approximately 0.64% of Perspective Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of CATX. ZWJ Investment Counsel Inc. acquired a new position in Perspective Therapeutics during the 1st quarter worth approximately $26,000. Bleakley Financial Group LLC bought a new stake in shares of Perspective Therapeutics during the first quarter worth $40,000. Victory Capital Management Inc. acquired a new position in shares of Perspective Therapeutics during the second quarter worth $117,000. RIA Advisory Group LLC lifted its stake in shares of Perspective Therapeutics by 1,313.4% in the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after acquiring an additional 99,293 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Perspective Therapeutics in the 1st quarter valued at $138,000. 54.66% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on CATX. Royal Bank of Canada lowered their target price on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a report on Friday, August 16th. Oppenheimer reduced their price target on Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating on the stock in a report on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Finally, Bank of America initiated coverage on shares of Perspective Therapeutics in a report on Thursday, July 25th. They set a “buy” rating and a $24.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $19.80.

Perspective Therapeutics Stock Performance

NYSE:CATX opened at $13.23 on Monday. Perspective Therapeutics, Inc. has a 52 week low of $2.20 and a 52 week high of $19.05. The company has a fifty day moving average price of $13.81.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. The business had revenue of $0.53 million for the quarter. Equities research analysts forecast that Perspective Therapeutics, Inc. will post -0.86 earnings per share for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.